IZERVAY® (avacincaptad pegol intravitreal solution) Demonstrated Increased Probability of Maintaining Driving Eligibility in Geographic Atrophy Patients
Go back to IZERVAY® (avacincaptad pegol intravitreal solution) Demonstrated Increased Probability of Maintaining Driving Eligibility in Geographic Atrophy Patients| Astellas Pharma Inc Unsponsored ADR (AMEX: ALPMY) | Delayed: 13.45 +0.15 (1.13%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.30 | 52 Week High | $19.40 | |||
| Open | $13.49 | 52 Week Low | $12.50 | |||
| Day High | $13.56 | P/E | N/A | |||
| Day Low | $13.42 | EPS | $0.00 | |||
| Volume | 213,798 | |||||
